Navigation path

EuroSIDA


HIV/AIDS

The EuroSIDA network 2000-200: Clinical and Virological Outcome of European Patients Infected with HIV
Framework programme:
5
Project number:
QLK2-CT-2000-00773
EC contribution:
€ 1 150 000
Duration:
48 months
Type:
CA
Starting date:
1 December 2000
Website:
http://www.cphiv.dk/EuroSIDA/tabid/59/Default.aspx

Keywords: HIV; AIDS; observational study; cohort; virology; clinical outcome

Summary:

The primary objective of the EuroSIDA study is to collect demographic, clinical, therapeutic and laboratory data on patients with HIV infection to determine the long-term virological and clinical outcome for patients from Europe. This knowledge will also be analysed, discussed and presented within the scientific community to assist physicians and public health officials.

Problem:

Despite recent improvement in the prognosis of HIV-infected patients from across Europe due to the use of powerful combination antiretroviral therapies, challenges persist in relation to the durability of responses and new co-morbidities. These challenges mainly concern development of resistance to existing treatments and coping with adverse drug reactions. In addition, there is a dramatic progression in the HIV epidemic in Eastern European countries requiring development of treatment strategies in this setting.

Aim:

The aim of this project is to continue a long-term, prospective collection of clinical, laboratory and therapeutic data as well as plasma on a large cohort of consecutive-HIV-infected patients from across Europe. This in order to assess the factors associated with the clinical, immunological and virological course of HIV infection, including the effect and toxicity of antiretroviral agents and other therapeutic interventions.

There will be a continuation of providing and developing a surveillance system to describe temporal changes and regional differences in the clinical course of HIV. These include:

1) the overall pattern of HIV-related diseases and death, and the emergence of new diseases, including drug-related diseases
2) the prevalence of patients with severe immunosuppression and high viral replication
3) the virological response to initial antiretroviral therapy.

[+] Read More